RESUMO
Chickpea hydrolysates have shown bioactivity towards type 2 diabetes by inhibiting dipeptidyl peptidase (DPPIV) activity. The objective was to compare the effect of adding different levels of an optimized bromelain hydrolysate from chickpea isolated protein on DPPIV inhibition capacity and physicochemical properties of maize tortilla. White and blue maize tortillas, with no added chickpea hydrolysates were compared with fortified tortillas at the levels of 5%, 10%, and 15% w/w. Changes in color (L* a* b*, hue angle, and ΔE), texture (hardness, cohesiveness, and puncture force), and moisture were tested. Soluble protein determination and SDS-PAGE electrophoresis were used to characterize the protein profiles, and LC-MS-MS was used to sequence the peptides. DPPIV inhibition was evaluated before and after simulated gastrointestinal digestion. Peptides in the hydrolysates had high hydrophobicity (7.97-27.05 kcal * mol -1) and pI (5.18-11.13). Molecular docking of peptides showed interaction with DPPIV with an energy of affinity of -5.8 kcal/mol for FDLPAL in comparison with vildagliptin (-6.2 kcal/mol). The lowest fortification level increased soluble protein in 105% (8 g/100 g tortilla). DPPIV inhibition of white maize tortilla increased from 11% (fresh control) to 91% (15% fortification), and for blue tortilla from 26% to 95%. After simulated digestion, there was not a difference between blue or maize tortillas for DPPIV inhibition. Fortification of maize tortilla with chickpea hydrolysate inhibits DPPIV and can potentially be used in the prevention and management of type 2 diabetes. However, due to observed physicochemical changes of the fortified tortilla, sensory properties and consumer acceptance need to be evaluated.
RESUMO
The objective was to compare five varieties of chickpea (Cicer arietinum), sequence the peptides obtained with pepsin-pancreatin digestion, and evaluate their potential as modulators of biochemical markers for type-2 diabetes. In addition, to produce a functional ingredient, by the optimization in the production of hydrolysates using bromelain. Proteins of ground raw, precooked and cooked chickpea, were extracted, isolated, and characterized using SDS-PAGE gel electrophoresis. Hydrolysates were obtained by simulated digestion with pepsin-pancreatin, and resulting peptides were sequenced with LC-MSMS. Response surface methodology was used to optimize the production of hydrolysates with dipeptidyl peptidase IV (DPPIV) inhibition using bromelain. Protein profiles showed fractions of convicilin (>70â¯kDa), 7S vicilin (43-53â¯kDa), 11S legumin (35â¯kDa) and lectins (30-32â¯kDa) in raw varieties. Albumin fractions 2S (20-26â¯kDa) were still present in most varieties after 2â¯h of heat treatment. DPPIV IC50 values from digestive enzymes were better (0.17-2.21â¯mg/mL) in raw chickpea than in cooked chickpea. α-Glucosidase inhibition at 10â¯mg protein/mL was highest (32-66%) in precooked chickpea hydrolysates. Hydrolysis with bromelain showed a DPPIV inhibition of 94% for Sierra variety cooked for 15â¯min with 1:10 E/S ratio and hydrolysis time of 60â¯min. Peptides with DPPIV inhibition were present from albumin fractions (EVLSEVSF) with 908.44â¯Da and high hydrophobicity; and from legumin (VVFW, FDLPAL) with 549.29 and 674.36â¯Da, respectively. In conclusion, high DDPIV inhibition can be obtained from chickpea bromelain hydrolysates, with potential as ingredients in different food applications.
Assuntos
Cicer , Diabetes Mellitus Tipo 2 , Biomarcadores , Peptídeos , alfa-GlucosidasesRESUMO
Chickpea (Cicer arietinum) is one of the most consumed pulses worldwide (over 2.3 million tons enter the world market annually). Some chickpea components have shown, in preclinical and clinical studies, several health benefits, including antioxidant capacity, and antifungal, antibacterial, analgesic, anticancer, antiinflammatory, and hypocholesterolemic properties, as well as angiotensin I-converting enzyme inhibition. In the United States, chickpea is consumed mostly in the form of hummus. However, the development of new products with value-added bioactivity is creating new opportunities for research and food applications. Information about bioactive compounds and functional properties of chickpea ingredients in the development of new products is needed. The objective of this review was to summarize available scientific information, from the last 15 years, on chickpea production, consumption trends, applications in the food industry in the elaboration of plant-based snacks, and on its bioactive compounds related to type 2 diabetes (T2D). Areas of opportunity for future research and new applications of specific bioactive compounds as novel food ingredients are highlighted. Research is key to overcome the main processing obstacles and sensory challenges for the application of chickpea as ingredient in snack preparations. The use of chickpea bioactive compounds as ingredient in food products is also a promising area for accessibility of their health benefits, such as the management of T2D.